Indications
Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.
Composition
- Active substance
- recombinant human n-acetylgalactosamine-6-sulfatase
- International name (INN)
- elosulfase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vimizim
- Active substance
- recombinant human n-acetylgalactosamine-6-sulfatase
- ATC code
- A16AB12
- Therapeutic area
- Mucopolysaccharidosis IV
- Marketing authorisation holder
- BioMarin International Limited